Advertisement

Picture EBD Group BioPharm America 2017 BPA Boston MA Startup September 600x60px
Document › Details

CRISPR Therapeutics AG. (7/5/17). "Presss Release: CRISPR Therapeutics to Present at the Piper Jaffray GenomeRx Symposium". Basel & Cambridge, MA.

Organisations Organisation CRISPR Therapeutics AG (Nasdaq: CRSP)
  Group CRISPR Therapeutics (Group)
  Organisation 2 Piper Jaffray & Co. (NYSE: PJC)
  Group Piper Jaffray (Group)
Products Product Piper Jaffray GenomeRx Symposium 2017 New York
  Product 2 CRISPR gene editing technology
Index term Index term CRISPR Therapeutics–Piper Jaffray: investor conference, 201707 supply service CRISPR Therapeutics presents at Piper Jaffray GenomeRx Symposium in NYC
Persons Person Novak, Rodger (CRISPR Therapeutics 201404 CEO before Sanofi + Nabriva GmbH)
  Person 2 Kulkarni, Samarth (Sam) (CRISPR Therapeutics 201703 CBO)
     


CRISPR Therapeutics (NASDAQ:CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced that Rodger Novak, M.D., Chief Executive Officer and Founder of CRISPR Therapeutics and Samarth Kulkarni, Ph.D., President and Chief Business Officer of CRISPR Therapeutics, will present at the Piper Jaffray GenomeRx Symposium at the New York Palace Hotel in New York, New York.

Event: Piper Jaffray GenomeRx Symposium
Panel: Gene Editing- Moving from Tools To Therapies
Date: Tuesday, July 11, 2017
Time: 12:05 PM EDT


About CRISPR Therapeutics

CRISPR Therapeutics is a leading gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR / Cas9 gene-editing platform. CRISPR / Cas9 is a revolutionary technology that allows for precise, directed changes to genomic DNA. The company's multi-disciplinary team of world-class researchers and drug developers is working to translate this technology into breakthrough human therapeutics in a number of serious diseases. Additionally, CRISPR Therapeutics has established strategic collaborations with Bayer AG and Vertex Pharmaceuticals to develop CRISPR-based therapeutics in diseases with high unmet need. The foundational CRISPR / Cas9 patent estate for human therapeutic use was licensed from the company's scientific founder Emmanuelle Charpentier, Ph.D. CRISPR Therapeutics AG is headquartered in Basel, Switzerland, with its wholly-owned U.S. subsidiary, CRISPR Therapeutics, Inc., and R&D operations based in Cambridge, Massachusetts. For more information, please visit http://www.crisprtx.com.


MEDIA CONTACTS:
Jennifer Paganelli
WCG on behalf of CRISPR
+1 347-658-8290
jpaganelli@wcgworld.com

INVESTOR CONTACT:
Chris Brinzey
Westwicke Partners for CRISPR
+1 339-970-2843
chris.brinzey@westwicke.com

   
Record changed: 2017-07-13

Advertisement

Picture EBD Group Bio-Europe 2017 BEU Berlin Germany November 600x60px

More documents for CRISPR Therapeutics (Group)


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Advertisement

Picture BIO Deutschland EBDC 2017 Heidelberg 600x60px




» top

Advertisements

Picture [iito] Twitter iitoLifeScience Life Sciences Mass Spec 120x120px Picture EBD Group Bio-Europe 2017 BEU Berlin Germany November 120x80px Picture BIO Deutschland EBDC 2017 Heidelberg 120x240px Picture EBD Group BioPharm America 2017 BPA Boston MA Startup September 120x80px Picture [LSE] Life-Sciences-Europe.com – The Business Web Portal 120x600px Banner Fairtec GmbH Solutions for Smarter Business Events Exhibitions 120x120px Picture [iito] Twitter iitoLifeScience Life Sciences Mass Spec 120x120px Picture BIO Deutschland EBDC 2017 Heidelberg 120x240px Picture EBD Group BioPharm America 2017 BPA Boston MA Startup September 120x80px Picture EBD Group Bio-Europe 2017 BEU Berlin Germany November 120x80px